Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1984 Sep;52(3):314–320. doi: 10.1136/hrt.52.3.314

Effects of vasodilator treatment with felodipine on haemodynamic responses to treadmill exercise in congestive heart failure.

A D Timmis, P Smyth, J F Kenny, S Campbell, D E Jewitt
PMCID: PMC481631  PMID: 6466518

Abstract

Treatment with vasodilators in heart failure has not always produced a useful improvement in the haemodynamic responses to exercise, and in many cases early drug tolerance has further limited the potential of this type of treatment. In a study to evaluate the efficacy of felodipine, a new calcium antagonist with selective vasodilator properties, in the management of congestive heart failure 10 patients with congestive heart failure underwent treadmill exercise testing before and during oral treatment with felodipine 30 mg daily. At every level of exercise felodipine lowered the pulmonary capillary wedge pressure, whereas cardiac index and stroke index increased considerably. The haemodynamic improvement was associated with an increase in the duration of exercise to exhaustion. Importantly, these beneficial effects were sustained throughout four weeks of treatment without evidence of drug tolerance. These observations suggest a useful role for felodipine in the long term management of congestive heart failure.

Full text

PDF
314

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bertel O., Burkart F., Bühler F. R. Sustained effectiveness of chronic prazosin therapy in severe chronic congestive heart failure. Am Heart J. 1981 May;101(5):529–533. doi: 10.1016/0002-8703(81)90217-9. [DOI] [PubMed] [Google Scholar]
  2. Bostróm S. L., Ljung B., Mårdh S., Forsen S., Thulin E. Interaction of the antihypertensive drug felodipine with calmodulin. Nature. 1981 Aug 20;292(5825):777–778. doi: 10.1038/292777a0. [DOI] [PubMed] [Google Scholar]
  3. Braunwald E. Mechanism of action of calcium-channel-blocking agents. N Engl J Med. 1982 Dec 23;307(26):1618–1627. doi: 10.1056/NEJM198212233072605. [DOI] [PubMed] [Google Scholar]
  4. Brooks N., Cattell M., Pidgeon J., Balcon R. Unpredictable response to nifedipine in severe cardiac failure. Br Med J. 1980 Nov 15;281(6251):1324–1324. doi: 10.1136/bmj.281.6251.1324. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Colucci W. S., Wynne J., Holman B. L., Braunwald E. Long-term therapy of heart failure with prazosin: a randomized double blind trial. Am J Cardiol. 1980 Feb;45(2):337–344. doi: 10.1016/0002-9149(80)90656-6. [DOI] [PubMed] [Google Scholar]
  6. Elkayam U., Lejemtel T. H., Mathur M., Ribner H. S., Frishman W. H., Strom J., Sonnenblick E. H. Marked early attenuation of hemodynamic effects of oral prazosin therapy in chronic congestive heart failure. Am J Cardiol. 1979 Sep;44(3):540–545. doi: 10.1016/0002-9149(79)90409-0. [DOI] [PubMed] [Google Scholar]
  7. Fleckenstein A. Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Annu Rev Pharmacol Toxicol. 1977;17:149–166. doi: 10.1146/annurev.pa.17.040177.001053. [DOI] [PubMed] [Google Scholar]
  8. Franciosa J. A., Cohn J. N. Effect of isosorbide dinitrate on response to submaximal and maximal exercise in patients with congestive heart failure. Am J Cardiol. 1979 May;43(5):1009–1014. doi: 10.1016/0002-9149(79)90368-0. [DOI] [PubMed] [Google Scholar]
  9. Franciosa J. A., Cohn J. N. Immediate effects of hydralazine-isosorbide dinitrate combination on exercise capacity and exercise hemodynamics in patients with left ventricular failure. Circulation. 1979 Jun;59(6):1085–1091. doi: 10.1161/01.cir.59.6.1085. [DOI] [PubMed] [Google Scholar]
  10. Franciosa J. A., Weber K. T., Levine T. B., Kinasewitz G. T., Janicki J. S., West J., Henis M. M., Cohn J. N. Hydralazine in the long-term treatment of chronic heart failure: lack of difference from placebo. Am Heart J. 1982 Sep;104(3):587–594. doi: 10.1016/0002-8703(82)90231-9. [DOI] [PubMed] [Google Scholar]
  11. Froelicher V. F., Jr, Brammell H., Davis G., Noguera I., Stewart A., Lancaster M. C. A comparison of the reproducibility and physiologic response to three maximal treadmill exercise protocols. Chest. 1974 May;65(5):512–517. doi: 10.1378/chest.65.5.512. [DOI] [PubMed] [Google Scholar]
  12. Gillmer D. J., Kark P. Pulmonary oedema precipitated by nifedipine. Br Med J. 1980 Jun 14;280(6229):1420–1421. doi: 10.1136/bmj.280.6229.1420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hindman M. C., Slosky D. A., Peter R. H., Newman G. E., Jones R. H., Wallace A. G. Rest and exercise hemodynamic effects of oral hydralazine in patients with coronary artery disease and left ventricular dysfunction. Circulation. 1980 Apr;61(4):751–758. doi: 10.1161/01.cir.61.4.751. [DOI] [PubMed] [Google Scholar]
  14. Klugmann S., Salvi A., Camerini F. Haemodynamic effects of nifedipine in heart failure. Br Heart J. 1980 Apr;43(4):440–446. doi: 10.1136/hrt.43.4.440. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Ludbrook P. A., Tiefenbrunn A. J., Reed F. R., Sobel B. E. Acute hemodynamic responses to sublingual nifedipine: dependence on left ventricular function. Circulation. 1982 Mar;65(3):489–498. doi: 10.1161/01.cir.65.3.489. [DOI] [PubMed] [Google Scholar]
  16. Massie B. M., Kramer B., Haughom F. Acute and long-term effects of vasodilator therapy on resting and exercise hemodynamics and exercise tolerance. Circulation. 1981 Dec;64(6):1218–1226. doi: 10.1161/01.cir.64.6.1218. [DOI] [PubMed] [Google Scholar]
  17. Packer M., Meller J., Gorlin R., Herman M. V. Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure. Circulation. 1979 Mar;59(3):531–539. doi: 10.1161/01.cir.59.3.531. [DOI] [PubMed] [Google Scholar]
  18. Polese A., Fiorentini C., Olivari M. T., Guazzi M. D. Clinical use of a calcium antagonistic agent (nifedipine) in acute pulmonary edema. Am J Med. 1979 May;66(5):825–830. doi: 10.1016/0002-9343(79)91123-9. [DOI] [PubMed] [Google Scholar]
  19. Proceedings of the british cardiac society. Br Heart J. 1984 Jan;51(1):101–120. [PMC free article] [PubMed] [Google Scholar]
  20. RAPAPORT E., WONG M., FERGUSON R. E., BERNSTEIN P., WIEGAND B. D. RIGHT VENTRICULAR VOLUMES IN PATIENTS WITH AND WITHOUT HEART FAILURE. Circulation. 1965 Apr;31:531–541. doi: 10.1161/01.cir.31.4.531. [DOI] [PubMed] [Google Scholar]
  21. Robson R. H., Vishwanath M. C. Nifedipine and beta-blockade as a cause of cardiac failure. Br Med J (Clin Res Ed) 1982 Jan 9;284(6309):104–104. doi: 10.1136/bmj.284.6309.104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Rubin S. A., Chatterjee K., Parmley W. W. Metabolic assessment of exercise in chronic heart failure patients treated with short-term vasodilators. Circulation. 1980 Mar;61(3):543–548. doi: 10.1161/01.cir.61.3.543. [DOI] [PubMed] [Google Scholar]
  23. Timmis A. D., Campbell S., Monaghan M. J., Walker L., Jewitt D. E. Acute haemodynamic and metabolic effects of felodipine in congestive heart failure. Br Heart J. 1984 Apr;51(4):445–451. doi: 10.1136/hrt.51.4.445. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Tweddel A. C., Johnsson G., Pringle T. H., Murray R. G., Hutton I. The systemic and coronary haemodynamic effects of felodipine in patients with coronary heart disease. Eur Heart J. 1983 Oct;4(10):699–705. doi: 10.1093/oxfordjournals.eurheartj.a061381. [DOI] [PubMed] [Google Scholar]
  25. Wallenstein S., Zucker C. L., Fleiss J. L. Some statistical methods useful in circulation research. Circ Res. 1980 Jul;47(1):1–9. doi: 10.1161/01.res.47.1.1. [DOI] [PubMed] [Google Scholar]
  26. Zelis R., Flaim S. F., Moskowitz R. M., Nellis S. H. How much can we expect from vasodilator therapy in congestive heart failure? Circulation. 1979 Jun;59(6):1092–1097. doi: 10.1161/01.cir.59.6.1092. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES